机构：[1]School of Medicine and Centre for Molecular and Medical Research, Deakin University, 75 Pigdons Road, WaurnPonds, Victoria, 3216, Australia[2]School of Nursing, Zhengzhou University, Zhengzhou, Henan Province, 450001,China[3]Centre for Comparative Genomics, Murdoch University, 90 South Street, Murdoch, WA, 6150, Australia[4]Suzhou GenePharma, 199 Dongping Street, Suzhou, 215123, China[5]Cancer Care Centre, St George Hospital andSt George and Suthland Clinical School, University of New South Wales (UNSW), High Street, Kensington, NSW2052, Australia[6]Deakin University, Institute for Frontier Materials, 75 Pigdons Road, Waurn Ponds, Victoria, 3216,Australia[7]College of Life Sciences, Sichuan University, No.24South Section 1, Yihuan Road, Chengdu, 610041, P.R.China[8]Department of Bioengineering and Biotechnology, College of Chemical Engineering, Huaqiao University,668 Jimei Avenue, Xiamen, Fujian, 361021, China[9]Center for Qinba Region’s Sustainable Development, ShaanxiNormal University, No.199, South Chang’an Road, Xi’an, Shaanxi, 710062, China
The development of chemoresistance and inability in elimination of cancer stem cells are among the key limitations of cancer chemotherapy. Novel molecular therapeutic strategies able to overcome such limitations are urgently needed for future effective management of cancer. In this report, we show that EpCAM-aptamer-guided survivin RNAi effectively downregulated survivin both in colorectal cancer cells in vitro and in a mouse xenograft model for colorectal cancer. When combined with the conventional chemotherapeutic agents, the aptamer-guided survivin RNAi was able to enhance the sensitivity towards 5-FU or oxaliplatin in colorectal cancer stem cells, increase apoptosis, inhibit tumour growth and improve the overall survival of mice bearing xenograft colorectal cancer. Our results indicate that survivin is one of the key players responsible for the innate chemoresistance of colorectal cancer stem cells. Thus, aptamer-mediated targeting of survivin in cancer stem cells in combination with chemotherapeutic drugs constitutes a new avenue to improve treatment outcome in oncologic clinics.
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2017]版：
大类|3 区综合性期刊
小类|3 区综合性期刊
最新[2023]版：
大类|2 区综合性期刊
小类|2 区综合性期刊
第一作者：
第一作者机构：[1]School of Medicine and Centre for Molecular and Medical Research, Deakin University, 75 Pigdons Road, WaurnPonds, Victoria, 3216, Australia
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Hadi AlShamaileh,Tao Wang,Dongxi Xiang,et al.Aptamer-mediated survivin RNAi enables 5-fluorouracil to eliminate colorectal cancer stem cells.[J].Scientific reports.2017,7(1):5898.doi:10.1038/s41598-017-05859-z.
APA：
Hadi AlShamaileh,Tao Wang,Dongxi Xiang,Wang Yin,Phuong Ha-Lien Tran...&Wei Duan.(2017).Aptamer-mediated survivin RNAi enables 5-fluorouracil to eliminate colorectal cancer stem cells..Scientific reports,7,(1)
MLA：
Hadi AlShamaileh,et al."Aptamer-mediated survivin RNAi enables 5-fluorouracil to eliminate colorectal cancer stem cells.".Scientific reports 7..1(2017):5898
